Maxigen Biotech Inc. (TPE:1783)
Taiwan
· Delayed Price · Currency is TWD 39.40
+1.30 (3.41%)
Apr 29, 2026, 1:30 PM CST
Maxigen Biotech Cash Flow Statement
Financials in millions TWD. Fiscal year is January - December.
Millions TWD. Fiscal year is Jan - Dec.
Fiscal Year | FY 2025 | FY 2024 | FY 2023 | FY 2022 | FY 2021 | 2020 - 2016 |
|---|---|---|---|---|---|---|
Period Ending | Dec '25 Dec 31, 2025 | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | 2020 - 2016 |
| Net Income | 265.31 | 190.17 | 165.83 | 139.4 | 87.67 | Upgrade
|
| Depreciation & Amortization | 32.03 | 26.85 | 27.24 | 29.05 | 32.31 | Upgrade
|
| Other Amortization | 0.11 | 0.18 | 0.37 | 0.53 | 0.59 | Upgrade
|
| Loss (Gain) From Sale of Assets | - | 0 | -13.62 | -1.03 | - | Upgrade
|
| Stock-Based Compensation | 3.13 | 6.69 | 7.69 | 13.48 | 2.45 | Upgrade
|
| Provision & Write-off of Bad Debts | -7.32 | 14.47 | 0.2 | 4.72 | 3.02 | Upgrade
|
| Other Operating Activities | 5.75 | 4.78 | -5.4 | 15.37 | 1.28 | Upgrade
|
| Change in Accounts Receivable | -31.02 | -29.78 | -3.8 | -12.26 | -6 | Upgrade
|
| Change in Inventory | -23.46 | 9.45 | -9.91 | 3.68 | 8.03 | Upgrade
|
| Change in Accounts Payable | 36.84 | 32.87 | -18.82 | -4.11 | 7.05 | Upgrade
|
| Change in Unearned Revenue | -7.83 | 21.6 | -2.92 | -6.88 | 7.36 | Upgrade
|
| Change in Other Net Operating Assets | 16.69 | 20.96 | 24.33 | 86.38 | -26.18 | Upgrade
|
| Operating Cash Flow | 290.22 | 298.22 | 171.2 | 268.34 | 117.59 | Upgrade
|
| Operating Cash Flow Growth | -2.68% | 74.20% | -36.20% | 128.19% | 57.71% | Upgrade
|
| Capital Expenditures | -81.87 | -31.77 | -22.44 | -14.29 | -14.26 | Upgrade
|
| Sale of Property, Plant & Equipment | - | - | 0.9 | 6.28 | - | Upgrade
|
| Sale (Purchase) of Intangibles | -0.77 | - | - | -0.15 | -1.19 | Upgrade
|
| Sale (Purchase) of Real Estate | - | - | 22.59 | - | - | Upgrade
|
| Investment in Securities | -300 | - | -491.27 | 16.56 | -13.74 | Upgrade
|
| Other Investing Activities | -0.36 | 2.7 | -0.03 | 2.04 | 26.41 | Upgrade
|
| Investing Cash Flow | -382.99 | -29.07 | -490.25 | 10.43 | -2.78 | Upgrade
|
| Short-Term Debt Issued | 100 | - | - | - | - | Upgrade
|
| Total Debt Issued | 100 | - | - | - | - | Upgrade
|
| Long-Term Debt Repaid | - | - | - | -0.95 | -2.49 | Upgrade
|
| Net Debt Issued (Repaid) | 100 | - | - | -0.95 | -2.49 | Upgrade
|
| Issuance of Common Stock | 0.39 | 28.69 | 0.96 | - | 247.35 | Upgrade
|
| Common Dividends Paid | -74.43 | -88.96 | -42.35 | - | -56.27 | Upgrade
|
| Dividends Paid | -74.43 | -88.96 | -42.35 | - | -56.27 | Upgrade
|
| Other Financing Activities | 4.7 | 0.54 | - | -0.1 | 0.1 | Upgrade
|
| Financing Cash Flow | 30.66 | -59.73 | -41.39 | -1.05 | 188.69 | Upgrade
|
| Foreign Exchange Rate Adjustments | -0.75 | -1.45 | 0.57 | -0.08 | 0.03 | Upgrade
|
| Net Cash Flow | -62.86 | 207.97 | -359.87 | 277.64 | 303.54 | Upgrade
|
| Free Cash Flow | 208.36 | 266.45 | 148.76 | 254.05 | 103.34 | Upgrade
|
| Free Cash Flow Growth | -21.80% | 79.12% | -41.44% | 145.85% | 61.91% | Upgrade
|
| Free Cash Flow Margin | 25.67% | 39.15% | 23.91% | 42.03% | 20.18% | Upgrade
|
| Free Cash Flow Per Share | 2.31 | 2.97 | 1.66 | 2.84 | 1.22 | Upgrade
|
| Cash Interest Paid | 0.04 | - | - | 0.07 | 0.2 | Upgrade
|
| Cash Income Tax Paid | 33.83 | 30.6 | 32.72 | 10.76 | 8.52 | Upgrade
|
| Levered Free Cash Flow | 105.01 | 186.08 | 91.4 | 209.69 | 71.5 | Upgrade
|
| Unlevered Free Cash Flow | 105.03 | 186.08 | 91.4 | 209.73 | 71.62 | Upgrade
|
| Change in Working Capital | -8.78 | 55.09 | -11.12 | 66.81 | -9.73 | Upgrade
|
Source: S&P Capital IQ. Standard template. Financial Sources.